OCREVUS
300mg/10mlOCREVUS300mg/10ml
OCREVUS (Ocrelizumab) 300mg/10ml is a humanized anti-CD20 monoclonal antibody for relapsing and primary progressive multiple sclerosis (PPMS).
Key Benefits
- First and only approved treatment for PPMS
- 46-47% relapse rate reduction vs IFNβ-1a in RMS
- Convenient twice-yearly (every 6 months) dosing
- Superior MRI outcomes — significant reduction in T1 Gd+ and new/enlarging T2 lesions
- Over 300,000 patients treated worldwide since 2017
Contact Us for Pricing
Get a written quote against a prescription within 24 hours for OCREVUS 300mg/10ml. Our team is available 24/7.
Direct line: +44 7429 917553
Prescription required
We do not proceed without one
Licensed Türkiye channels
İTS serial-traceable by karekod
Delivered in person
Not shipped by courier
Written reply
Quote within 24 hours
How OCREVUS Works
Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-expressing B lymphocytes. It depletes CD20+ B cells through antibody-dependent cellular cytolysis (ADCC) and complement-dependent cytolysis (CDC), reducing the inflammatory and neurodegenerative processes driving MS.
About OCREVUS 300mg/10ml
OCREVUS (Ocrelizumab) 300mg/10ml by Roche/Genentech is a breakthrough humanized anti-CD20 monoclonal antibody that has transformed the treatment of multiple sclerosis. It is the first and only FDA-approved disease-modifying therapy for primary progressive MS (PPMS), based on the landmark ORATORIO trial. In two Phase III trials (OPERA I and OPERA II), Ocrevus demonstrated 46-47% reduction in annualized relapse rates compared to interferon beta-1a (Rebif) in relapsing MS. The convenience of twice-yearly dosing (every 6 months) has made it one of the most prescribed MS therapies worldwide, with over 300,000 patients treated since approval in 2017. Working through licensed Turkish pharmacy channels, we provide authentic Roche OCREVUS with complete cold chain handling, batch and expiry documentation, and a written quote against a prescription, usually within 24 hours for hospitals, MS treatment centers, and pharmaceutical distributors worldwide.
Common Uses
- Relapsing forms of multiple sclerosis (RMS)
- Primary progressive multiple sclerosis (PPMS)
- Clinically isolated syndrome (CIS)
- Active secondary progressive MS
Dosage Information
Initial: 300mg IV on Day 1, then 300mg IV on Day 15. Subsequent: 600mg IV every 6 months (24 weeks). Infuse over 2.5-3.5 hours with required pre-medication. Monitor for 1 hour post-infusion.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. After dilution in 0.9% NaCl: stable 24 hours at 2-8°C or 8 hours at room temperature including infusion time.
We ensure proper cold chain handling during shipping to maintain product integrity.
Full prescribing monograph
A single reference page compiled from the manufacturer's prescribing information and the regulator's public product data. No pricing is published on it.
Frequently Asked Questions About OCREVUS
Find answers to common questions about ordering, pricing, and shipping.
Related Rheumatology & Immune Products
Explore more rheumatology & immune medications from our catalog
